22.03.2023 • NewsNovartisBiogen

Sangamo Reviews Options as Drugmakers Terminate Deals

US biotech Sangamo Therapeutics is studying alternative options to advance its neurological disease programs after both Novartis and Biogen ended their respective collaborations. The California-based company said options could include potentially developing the programs internally, or with another partner.

Novartis Institutes for BioMedical Research was the first to move, giving notice on Mar. 13 that it was terminating its agreement with effect from Jun. 11, 2023. Under an agreement signed in July 2020, the partners were engaged in programs to research gene regulation therapies to treat three neurodevelopmental disorders. Novartis told Sangamo that its termination relates to a recent strategic review.

Four days later — on Mar. 17 — Biogen notified Sangamo that it would end its February 2020 agreement effective Jun. 15, 2023, also citing a recent strategic review as the reason. The program was focused on developing gene regulation therapies for Alzheimer’s, Parkinson’s, a neuromuscular target and nine other undisclosed neurological targets.

Sangamo said it believes it has enough cash and marketable securities to fund operations for at least 12 months from February 2023.

Author: Elaine Burridge, Freelance Journalist

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.